Paper Details

  1. Home
  2. Paper Details

Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery.

Author: CotilloIgnacio, De RyckerManu, GrayDavid W, LewisMichael D, MacLeanLorna M, ThomasJohn

Evaluation StudyResearch that systematically evaluates the effectiveness of a particular program or policy. It measures its outcomes and provides important information for future decision-making.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study explores the limitations of posaconazole, an ergosterol biosynthesis inhibitor, in treating Chagas' disease. The authors found that posaconazole's effectiveness is limited by the slow doubling and cycling time of some T. cruzi strains. In contrast, benznidazole effectively killed all parasites, highlighting its potential for further development.
Paper Details　
Original Abstract of the Article :
Chagas' disease is responsible for significant mortality and morbidity in Latin America. Current treatments display variable efficacy and have adverse side effects, hence more effective, better tolerated drugs are needed. However, recent efforts have proved unsuccessful with failure of the ergostero...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057682/

データ提供：米国国立医学図書館（NLM）

Developing In Vitro Assays to Identify Promising Chagas' Disease Drug Candidates

Chagas' disease, a neglected tropical disease, poses a significant health burden in Latin America. Current treatments have limited efficacy and adverse side effects, necessitating the development of more effective and safer drugs. This research investigates the development of in vitro assays to identify promising drug candidates for Chagas' disease. The authors utilized a panel of *Trypanosoma cruzi* strains to evaluate the activity of various drugs, including posaconazole, nifurtimox, and benznidazole. The study aimed to improve the drug discovery process by identifying assays that can accurately predict clinical outcomes and identify compounds with the most potential for translation to human trials.

Navigating the Sands of Drug Discovery

Drug discovery is a long and arduous journey, like a camel traversing a vast desert. This study explores the development of in vitro assays to navigate this challenging landscape, helping researchers to identify the most promising drug candidates for Chagas' disease. The study's findings provide valuable insights into the complexities of drug discovery and the importance of developing robust assays that can accurately predict clinical outcomes.

Improving Treatment for Chagas' Disease

The development of effective treatments for Chagas' disease is crucial for improving the health and well-being of millions of people worldwide. This study's focus on developing improved in vitro assays represents a significant step forward in the fight against this neglected tropical disease.

Dr.Camel's Conclusion

This study sheds light on the crucial role of in vitro assays in identifying promising drug candidates for Chagas' disease. The findings highlight the importance of developing robust assays that can accurately predict clinical outcomes, paving the way for the development of more effective and safer treatments. As a camel navigating a vast desert, we must continually search for solutions that alleviate the suffering of those affected by neglected tropical diseases, ensuring that no one is left behind in the pursuit of better health.

Date :
  1. Date Completed 2018-12-11
  2. Date Revised 2023-03-15
Further Info :

Pubmed ID

30001347

DOI: Digital Object Identifier

PMC6057682

Related Literature

Article Analysis
・Side Effects of posaconazole
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.